Background The advent of short-course, curative treatment with direct-acting antivirals (DAA)
has given promise for the global elimination of hepatitis C virus (HCV) infections by 2030 …

The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic
hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases …

Background & Aims Direct-acting antiviral (DAA) regimens provide a cure in> 95% of
patients with chronic HCV infection. However, in some patients in whom therapy fails …

Background: In the Netherlands, unrestricted access to direct-acting antivirals (DAAs) halved
the incidence of acute hepatitis C virus (HCV) infections among HIV-infected men who have …

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …

The hepatitis C virus (HCV) prevalence is high among men who have sex with men (MSM)
with HIV in the Netherlands. Large reductions in HCV incidence among MSM with HIV …

Objective: We aimed to evaluate the frequency and associated factors of baseline NS5A
resistance-associated substitutions (RASs) in patients coinfected with human …

The recent detection of hepatitis C virus genotype 4 infection in human immunodeficiency
virus–infected patients prompted performing molecular characterization of these isolates. All …

После появления препаратов прямого противовирусного действия (ПППД) для
этиотропной терапии хронического гепатита С (ХГС) стало возможным внедрение …

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …